"Our total addressable market is $47 billion."

The investor across the table doesn't even look up from their laptop.

"Walk me through that."

You pause. Pull up your deck. Point to a slide citing a market research report.

"The global cardiovascular device market is $47 billion, and we're targeting a segment of that."

"Which segment?"

"Well… interventional cardiology. Specifically structural heart."

"How many hospitals can actually buy your device?"

Longer pause.

"We're still refining that number."

The meeting is over. You just don't know it yet.

Why Most TAM Calculations Kill Credibility

I've watched hundreds of MedTech pitches over 25 years. The pattern is always the same.

Founders open with massive TAM numbers pulled from industry reports. Billions of dollars. Global markets. Impressive charts.

Then investors ask one simple question: "How did you calculate that?"

And the whole thing falls apart.

Here's the problem: most TAM calculations aren't decision-making tools. They're fundraising artifacts designed to look impressive on slides.

Top-down math. Global extrapolations. Category-level reports with no connection to actual buyers.

Investors see through it immediately.

Because a TAM that can't be defended operationally isn't credible. And if your market sizing isn't credible, everything else you say becomes suspect.

What Investors Actually Want to See

Market size isn't about impressing people with big numbers.

It's about proving you understand:

• Who can actually buy your product

• How many of them exist

• What they'll realistically pay

• Why your assumptions hold up under scrutiny

A credible TAM should be explainable in under 60 seconds. Verbally. Without slides.

If you can't do that, your market sizing needs work.

The Bottom-Up TAM Framework

There's a better way to calculate TAM—one that builds investor confidence instead of killing it.

It starts with a simple principle: count buyer units, not market categories.

Step 1: Define Your Buyer Unit

The buyer unit is the foundation of all market sizing.

You cannot calculate TAM until you explicitly define who buys your product.

Not "hospitals." Not "cardiologists." Not "the healthcare system."

Specific buyer units with specific attributes.

Examples of valid buyer units:

• Hospitals with more than 300 beds and existing cardiac cath labs

• ASCs performing more than 500 orthopedic procedures annually

• Interventional radiology practices with 24/7 stroke coverage and mechanical thrombectomy programs

If you can't clearly articulate your buyer unit, stop. Your TAM calculation will be worthless.

Step 2: Count Eligible Buyer Units

Once your buyer unit is defined, count how many exist in your target market.

Use public datasets. Industry associations. Registry data. Defensible estimates clearly labeled as such.

Example:

"There are 247 Level 1 Trauma Centers in the United States with comprehensive stroke centers and existing mechanical thrombectomy programs performing 50+ cases annually."

That's a number you can defend. It's specific. It's verifiable. An investor can challenge your assumptions, but they can't dismiss the methodology.

Compare that to:

"The U.S. stroke treatment market includes 5,000+ hospitals."

One is precise. The other is useless.

Step 3: Apply Realistic Annual Pricing

What will buyers actually pay? Not list price. Not aspirational pricing. Realized value.

Use:

• Pilot pricing from early customers

• Comparable device purchase data

• Conservative willingness-to-pay assumptions based on buyer interviews

If your device will realistically sell for $45K per unit with hospitals buying 2-3 units in year one, use that number.

Don't inflate to $85K because "that's what we'll charge enterprise accounts eventually."

Investors price at risk. Conservative assumptions build credibility.

Step 4: Calculate TAM (Bottom-Up)

Now you have the pieces:

TAM = Number of Eligible Buyer Units × Realistic Annual Price

Example:

247 Level 1 Trauma Centers × $90K average annual spend (2 units at $45K) = $22.2M TAM

Is $22M smaller than $47 billion? Yes.

Is it defensible? Absolutely.

Will it close investor conversations or kill them? Close them.

Because you just proved you understand your market at a granular level. You're not guessing. You're not inflating. You've done the work.

Step 5: Calculate SAM (Serviceable Available Market)

TAM is theoretical maximum. SAM is a realistic maximum based on real constraints.

What limits your ability to service the entire TAM?

• Geography (you're U.S.-only for regulatory reasons)

• Sales capacity (you can only cover East Coast in year one)

• Care setting eligibility (only comprehensive stroke centers, not all trauma centers)

• Adoption readiness (only facilities with existing thrombectomy programs, not greenfield)

SAM = TAM × Percentage Realistically Serviceable

Example:

$22.2M TAM × 35% realistically serviceable in year one (East Coast facilities with existing programs and budget authority) = $7.8M SAM

This percentage must be explained and justified. Don't just multiply by a random number.

Show your work:

• 86 of 247 trauma centers are East Coast = 35%

• Of those, 78 have active thrombectomy programs = 32%

• Of those, 64 have demonstrated willingness to adopt new technology based on peer influence patterns = 26%

Pick the constraint that matters most. Defend it.

Step 6: SOM (Optional—Execution Reality)

Serviceable Obtainable Market reflects what you'll actually capture, not what's theoretically available.

For early-stage companies, SOM typically ranges from 1-5% of SAM unless you have strong traction proving otherwise.

Example:

$7.8M SAM × 3% realistic market capture in year one = $234K SOM

Is that smaller than your revenue projection? It should be.

Because SOM is floor, not ceiling. It's the number you're confident you can defend. Your actual performance might exceed it—but you're not betting the business on best-case scenarios.

What This Framework Avoids

This bottom-up approach explicitly avoids the traps that kill credibility:

Top-down market sizing
"The global cardiovascular device market is $47B, and we'll capture 2%."

That's not a TAM. That's a guess multiplied by hope.

Inflated global TAMs without regulatory proof
"Our TAM is $200M globally."

Great. You have FDA clearance. Do you have CE mark? PMDA approval? ANVISA? No? Then your TAM is U.S.-only until you do.

Feature-based market math
"Anyone who does X procedure could use our device, so our TAM is…"

Could use ≠ will buy. Define who will actually pay, not who theoretically could.

Numbers you can't defend operationally
If an investor asks "how did you get that number?" and you can't walk them through your assumptions in 30 seconds, your TAM needs work.

Why This Actually Matters

Market sizing isn't just a fundraising exercise.

It's a decision-making tool that tells you:

• Where to focus sales efforts (highest-value buyer units first)

• How to allocate resources (geographic priorities, market entry sequencing)

• What success looks like (realistic milestones based on obtainable market)

• Whether your business model works (unit economics at realistic scale)

A credible TAM built from the bottom up doesn't just close investor conversations.

It makes you a better operator.

Because you're no longer selling into an abstract "$47 billion market." You're selling to 247 specific facilities with specific buying patterns, specific budget cycles, and specific decision-makers you can name.

That's the difference between strategy and hope.

The Final Rule: Clarity Over Impressiveness

Credible market sizing prioritizes clarity over big numbers.

A $20M defensible TAM beats a $2B fictional one. Every time.

Because investors aren't impressed by the size of your market. They're impressed by the depth of your understanding.

When you can verbally explain:

• Exactly who buys your product (buyer unit definition)

• Exactly how many exist (counted, not estimated from category reports)

• Exactly what they'll pay (realistic pricing, not aspirational)

• Exactly why your assumptions hold up (defended operationally, not theoretically)

You've just separated yourself from 90% of pitches investors hear.

Not because your market is bigger.

Because your thinking is clearer.

How Market Research Validates Your TAM

Here's where most founders get it wrong: they build TAM in a spreadsheet, then go looking for data to support it.

Backwards.

Real market sizing starts with research:

Customer interviews
Talk to 15-20 potential buyers. Understand their current workflows, pain points, budget authority, purchase cycles, and what would actually trigger a switch.

Those conversations tell you:

• If your buyer unit definition is accurate

• What realistic pricing looks like

• What constraints limit your SAM

• Whether your assumptions survive contact with reality

Win/loss analysis
If you have early pilots or sales, analyze what closed deals versus what killed them.

Patterns emerge:

• Facility size matters (only hospitals above X beds convert)

• Procedure volume is a gate (only practices doing Y+ cases annually buy)

• Existing technology matters (greenfield is harder than replacement)

Use those patterns to refine your buyer unit definition and SAM constraints.

Competitive intelligence
Who else is selling into this market? What's their penetration? What's their pricing?

If a comparable device has been on market for 3 years and penetrated 8% of eligible facilities, your 15% year-one SOM projection probably needs adjustment.

Market research doesn't inflate your TAM. It makes it defensible.

And defensible beats impressive every single time.

Ready to build credible market sizing that closes investor conversations?
The GTM Mini-Sprint™ includes bottom-up TAM/SAM validation as part of commercial foundation building. Limited Q2 slots available.
Apply at tribeconsulting.co